

Amendment No. 1

COMMITTEE/SUBCOMMITTEE ACTION

ADOPTED	<u> </u>	(Y/N)
ADOPTED AS AMENDED	<u> </u>	(Y/N)
ADOPTED W/O OBJECTION	<u> </u>	(Y/N)
FAILED TO ADOPT	<u> </u>	(Y/N)
WITHDRAWN	<u> </u>	(Y/N)
OTHER	<u> </u>	

Committee/Subcommittee hearing bill: Insurance & Banking
Subcommittee

Representative Nuñez offered the following:

Amendment (with title amendment)

Remove lines 49-57 and insert:

provides coverage for abuse-deterrent opioid analgesic drug
products:

(a) May impose a prior authorization requirement for an
abuse-deterrent opioid analgesic drug product only if the policy
imposes the same prior authorization requirement for each opioid
analgesic drug product without an abuse-deterrence labeling
claim.

(b) May not require use of an opioid analgesic drug
product without an abuse-deterrence labeling claim before
authorizing the use of an abuse-deterrent opioid analgesic drug

Amendment No. 1

18
19
20
21
22
23
24
25
26
27
28

T I T L E A M E N D M E N T

Remove lines 5-13 and insert:

abuse-deterrent opioid analgesic drug products may impose a
prior authorization requirement for an abuse-deterrent opioid
analgesic drug product only if the insurer imposes the same
requirement for each opioid analgesic drug product without an
abuse-deterrence labeling claim; prohibiting such health
insurance policy from requiring use of an opioid analgesic drug
product without an abuse-deterrence labeling claim before
authorizing use of an abuse-deterrent opioid